Sientra (SIEN) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SIEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SIEN, but not buy additional shares or sell existing shares.
View SIEN analyst ratings or view top-rated stocks.

Sientra, Inc. (NASDAQ:SIEN) released its quarterly earnings results on Wednesday, November, 10th. The medical instruments supplier reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.60) by $1.80. The medical instruments supplier had revenue of $19.62 million for the quarter, compared to analyst estimates of $18.10 million. During the same quarter in the prior year, the company posted ($3.30) EPS.

Sientra shares reverse split before market open on Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).